These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 26982554)

  • 1. Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes.
    Arakaki RF
    Postgrad Med; 2016 May; 128(4):409-17. PubMed ID: 26982554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes.
    Schwartz SS; Ahmed I
    Curr Med Res Opin; 2016 May; 32(5):907-19. PubMed ID: 26854518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the Kidney in Type 2 Diabetes and Mechanism of Action of Sodium Glucose Cotransporter-2 Inhibitors.
    Mintz ML
    J Fam Pract; 2016 Dec; 65(12 Suppl):. PubMed ID: 28149983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse effects and safety of SGLT-2 inhibitors.
    Halimi S; Vergès B
    Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S28-34. PubMed ID: 25554069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria.
    Geerlings S; Fonseca V; Castro-Diaz D; List J; Parikh S
    Diabetes Res Clin Pract; 2014 Mar; 103(3):373-81. PubMed ID: 24529566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Urinary tract infections in patients with type 2 diabetes mellitus with pharmacological glucosuria].
    Sturov NV; Popov SV; Mamporia NK; Mager AA
    Ter Arkh; 2020 Dec; 92(11):106-109. PubMed ID: 33720614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary tract infections and genital mycotic infections associated with SGLT‑2 inhibitors: an analysis of the FDA Adverse Event Reporting System.
    Yang T; Zhou Y; Cui Y
    Expert Opin Drug Saf; 2024 Aug; 23(8):1035-1040. PubMed ID: 38009230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials.
    Li D; Wang T; Shen S; Fang Z; Dong Y; Tang H
    Diabetes Obes Metab; 2017 Mar; 19(3):348-355. PubMed ID: 27862830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genitourinary infections in diabetic patients in the new era of diabetes therapy with sodium-glucose cotransporter-2 inhibitors.
    Rizzi M; Trevisan R
    Nutr Metab Cardiovasc Dis; 2016 Nov; 26(11):963-970. PubMed ID: 27514605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.
    Nicolle LE; Capuano G; Ways K; Usiskin K
    Curr Med Res Opin; 2012 Jul; 28(7):1167-71. PubMed ID: 22548646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of the Kidney and SGLT2 Inhibitors in Type 2 Diabetes.
    Katz PM; Leiter LA
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S167-75. PubMed ID: 26654860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence.
    Scheen AJ; Paquot N
    Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S4-S11. PubMed ID: 25554070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary and genital infections in patients with diabetes: How to diagnose and how to treat.
    Njomnang Soh P; Vidal F; Huyghe E; Gourdy P; Halimi JM; Bouhanick B
    Diabetes Metab; 2016 Feb; 42(1):16-24. PubMed ID: 26323665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
    Woo V; Connelly K; Lin P; McFarlane P
    Curr Med Res Opin; 2019 Jul; 35(7):1283-1295. PubMed ID: 30767677
    [No Abstract]   [Full Text] [Related]  

  • 15. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.
    Abdul-Ghani MA; Norton L; Defronzo RA
    Endocr Rev; 2011 Aug; 32(4):515-31. PubMed ID: 21606218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus.
    Raskin P
    Diabetes Metab Res Rev; 2013 Jul; 29(5):347-56. PubMed ID: 23463735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empagliflozin for the treatment of Type 2 diabetes.
    Gangadharan Komala M; Mather A
    Expert Rev Clin Pharmacol; 2014 May; 7(3):271-9. PubMed ID: 24716752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study.
    Dave CV; Schneeweiss S; Kim D; Fralick M; Tong A; Patorno E
    Ann Intern Med; 2019 Aug; 171(4):248-256. PubMed ID: 31357213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits/risks of sodium-glucose co-transporter 2 inhibitor canagliflozin in women for the treatment of Type 2 diabetes.
    Kushner P
    Womens Health (Lond); 2016 Jun; 12(3):379-88. PubMed ID: 26928259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.